{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:46:42Z","timestamp":1793249202888,"version":"4.5.0"},"reference-count":71,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Background\/Objectives: Parkinson\u2019s disease (PD) and Dementia with Lewy Bodies (DLB) are neurodegenerative disorders characterized by the accumulation of misfolded alpha-synuclein protein in the brain. Mutations in the glucocerebrosidase 1 (GBA1) gene have been identified as a significant genetic risk factor for both PD and DLB. GBA1 encodes for the lysosomal enzyme glucocerebrosidase, which is responsible for the breakdown of glucosylceramide (GC). Deficiencies in glucocerebrosidase activity lead to the accumulation of glucosylceramide within lysosomes, contributing to lysosomal dysfunction and impaired protein degradation. The aim of this narrative review is to update the underlying mechanisms by which GBA1 mutations contribute to the pathogenesis of PD and DLB. Methods: A comprehensive literature search was conducted across four major electronic databases (PubMed, Web of Science (Core Collection), Scopus, and Embase) from inception to 8 November 2025. The initial search identified approximately 1650 articles in total, with the number of hits from each database being as follows: PubMed (~450), Web of Science (~380), Scopus (~520), and Embase (~300). Results: The mechanism by which mutations in the GBA1 gene contribute to PD involves both loss-of- function and gain-of-function pathways, which are not mutually exclusive. Typically, GBA1 mutations lead to a loss of function by reducing the activity of the GCase enzyme, impairing the autophagy- lysosomal pathway and leading to \u03b1-synuclein accumulation. However, some mutant forms (GBA1L444P) of the GCase enzyme can also acquire a toxic gain of function, contributing to \u03b1-synuclein aggregation through mechanisms like endoplasmic reticulum stress and misfolding. While Venglustat effectively reduced GC levels, a key marker associated with GBA1-PD, the lack of clinical improvement led to the discontinuation of its development for this indication. Conclusions: GBA1-mediated lysosomal and lipid dysregulation represents a key pathogenic axis in PD and DLB. Understanding these mechanisms provides crucial insight into disease progression and highlights emerging therapeutic strategies\u2014such as pharmacological chaperones, substrate reduction therapies, and gene-targeted approaches\u2014aimed at restoring GCase function and lysosomal homeostasis to slow or prevent neurodegeneration.<\/jats:p>","DOI":"10.3390\/genes16121496","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:32:37Z","timestamp":1765805557000},"page":"1496","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Underlying Mechanisms of GBA1 in Parkinson\u2019s Disease and Dementia with Lewy Bodies: Narrative Review"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3006-8711","authenticated-orcid":false,"given":"Anastasia","family":"Bougea","sequence":"first","affiliation":[{"name":"1st Department of Neurology, Medical School, National and Kapodistrian University of Athens, 72 Vas. Sophias Ave, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/bs.acc.2020.08.007","article-title":"Synuclein in neurodegeneration","volume":"103","author":"Bougea","year":"2021","journal-title":"Adv. Clin. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00702-022-02531-3","article-title":"Glucocerebrosidase mutations and Parkinson disease","volume":"129","author":"Vieira","year":"2022","journal-title":"J. Neural Transm."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1093\/brain\/awx285","article-title":"Excessive burden of lysosomal storage disorder gene variants in Parkinson\u2019s disease","volume":"140","author":"Robak","year":"2017","journal-title":"Brain A J. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1212\/WNL.0b013e318245f476","article-title":"Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers","volume":"78","author":"Anheim","year":"2012","journal-title":"Neurology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1002\/mds.28200","article-title":"Penetrance of Glucocerebrosidase (GBA) Mutations in Parkinson\u2019s Disease: A Kin Cohort Study","volume":"35","author":"Balestrino","year":"2020","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Smith, L., and Schapira, A.H.V. (2022). GBA Variants and Parkinson Disease: Mechanisms and Treatments. Cells, 11.","DOI":"10.3390\/cells11081261"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40035-023-00363-z","article-title":"Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models","volume":"12","author":"Drobny","year":"2023","journal-title":"Transl. Neurodegener."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00401-024-02781-3","article-title":"Current insights and assumptions on \u03b1-synuclein in Lewy body disease","volume":"148","author":"Leak","year":"2024","journal-title":"Acta Neuropathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.4103\/1673-5374.382238","article-title":"Biochemical consequences of glucocerebrosidase 1 mutations in Parkinson\u2019s disease","volume":"19","author":"Yoon","year":"2024","journal-title":"Neural Regen. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40035-024-00437-6","article-title":"Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson\u2019s disease","volume":"13","author":"Zhang","year":"2024","journal-title":"Transl. Neurodegener."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6754","DOI":"10.1007\/s12035-024-04008-8","article-title":"The Molecular Impact of Glucosylceramidase Beta 1 (Gba1) in Parkinson\u2019s Disease: A New Genetic State of the Art","volume":"61","author":"Mano","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1590\/0004-282x20190006","article-title":"GBA mutations p.N370S and p.L444P are associated with Parkinson\u2019s disease in patients from Northern Brazil","volume":"77","author":"Amaral","year":"2019","journal-title":"Arq. Neuro-Psiquiatr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/brain\/awz350","article-title":"Genetic modifiers of risk and age at onset in GBA associated Parkinson\u2019s disease and Lewy body dementia","volume":"143","author":"Blauwendraat","year":"2020","journal-title":"Brain A J. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41531-022-00397-6","article-title":"Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology","volume":"8","author":"Riera","year":"2022","journal-title":"npj Park. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/mds.27659","article-title":"Parkinson\u2019s disease age at onset genome-wide association study: Defining heritability, genetic loci, and \u03b1-synuclein mechanisms","volume":"34","author":"Blauwendraat","year":"2019","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_16","first-page":"1208","article-title":"Faster disease progression in Parkinson\u2019s disease with glucocerebrosidase genotype: But not apparent immediate from diagnosis","volume":"15","author":"Frequin","year":"2025","journal-title":"J. Park. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/mds.30006","article-title":"Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson\u2019s Disease","volume":"39","author":"Vieira","year":"2024","journal-title":"Mov. Disord."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"107854","DOI":"10.1016\/j.parkreldis.2025.107854","article-title":"Combined assessment of blood glucocerebrosidase activity and \u03b1-synuclein levels in GBA1 mutation carriers: A novel potential biomarker","volume":"135","author":"Avenali","year":"2025","journal-title":"Park. Relat. Disord."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13024-019-0336-2","article-title":"Glucocerebrosidase and its relevance to Parkinson disease","volume":"14","author":"Do","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1089\/ars.2015.6307","article-title":"Sustained Systemic Glucocerebrosidase Inhibition Induces Brain \u03b1-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice","volume":"23","author":"Rocha","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"ref_21","first-page":"2645","article-title":"Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson\u2019s disease","volume":"25","author":"Rockenstein","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"105612","DOI":"10.1016\/j.nbd.2022.105612","article-title":"A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration","volume":"163","author":"Polissidis","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Sucunza, D., Rico, A.J., Roda, E., Collantes, M., Gonz\u00e1lez-Aseguinolaza, G., Rodr\u00edguez-P\u00e9rez, A.I., Pe\u00f1uelas, I., V\u00e1zquez, A., Labandeira-Garc\u00eda, J.L., and Broccoli, V. (2021). Glucocerebrosidase Gene Therapy Induces Alpha-Synuclein Clearance and Neuroprotection of Midbrain Dopaminergic Neurons in Mice and Macaques. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094825"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1093\/hmg\/ddw185","article-title":"Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: Relevance to Parkinson disease","volume":"25","author":"Magalhaes","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wang, H., Zhu, Y., Liu, H., Liang, T., and Wei, Y. (2023). Advances in Drug Discovery Targeting Lysosomal Membrane Proteins. Pharmaceuticals, 16.","DOI":"10.3390\/ph16040601"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Smith, J.K., Mellick, G.D., and Sykes, A.M. (2022). The role of the endolysosomal pathway in \u03b1-synuclein pathogenesis in Parkinson\u2019s disease. Front. Cell. Neurosci., 16.","DOI":"10.3389\/fncel.2022.1081426"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13024-024-00713-z","article-title":"GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice","volume":"19","author":"Gregorio","year":"2024","journal-title":"Mol. Neurodegener."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kiechle, M., Grozdanov, V., and Danzer, K.M. (2020). The Role of Lipids in the Initiation of \u03b1-Synuclein Misfolding. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.562241"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/brain\/awab371","article-title":"Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote \u03b1-synuclein aggregation","volume":"145","author":"Galvagnion","year":"2022","journal-title":"Brain A J. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40035-022-00281-6","article-title":"LRRK2, GBA and their interaction in the regulation of autophagy: Implications on therapeutics in Parkinson\u2019s disease","volume":"11","author":"Pang","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"168023","DOI":"10.1016\/j.jmb.2023.168023","article-title":"Mechanisms of Glucocerebrosidase Dysfunction in Parkinson\u2019s Disease","volume":"435","author":"Chatterjee","year":"2023","journal-title":"J. Mol. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/hmg\/ddaf062","article-title":"The modifying effect of mutant LRRK2 on mutant GBA1-associated Parkinson disease","volume":"34","author":"Egulsky","year":"2025","journal-title":"Hum. Mol. Genet."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Siwecka, N., Saramowicz, K., Galita, G., Rozp\u0119dek-Kami\u0144ska, W., and Majsterek, I. (2023). Inhibition of Protein Aggregation and Endoplasmic Reticulum Stress as a Targeted Therapy for \u03b1-Synucleinopathy. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15082051"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1038\/s41467-023-42107-7","article-title":"Glucocerebrosidase mutations disrupt the lysosome and now the mitochondria","volume":"14","author":"Klein","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.stemcr.2016.01.013","article-title":"ER Stress and Autophagic Perturbations Lead to Elevated Extracellular \u03b1-Synuclein in GBA-N370S Parkinson\u2019s iPSC-Derived Dopamine Neurons","volume":"6","author":"Fernandes","year":"2016","journal-title":"Stem Cell Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41531-025-00902-7","article-title":"Lysophosphatidylcholine promoting \u03b1-Synuclein aggregation in Parkinson\u2019s disease: Disrupting GCase glycosylation and lysosomal \u03b1-Synuclein degradation","volume":"11","author":"Mu","year":"2025","journal-title":"npj Park. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","article-title":"Glucosylsphingosine Promotes \u03b1-Synuclein Pathology in Mutant GBA-Associated Parkinson\u2019s Disease","volume":"37","author":"Taguchi","year":"2017","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/brain\/awae365","article-title":"Lewy pathology formation in patient-derived GBA1 Parkinson\u2019s disease midbrain organoids","volume":"148","author":"Frattini","year":"2025","journal-title":"Brain A J. Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ymgme.2012.11.010","article-title":"Membrane-bound \u03b1-synuclein interacts with glucocerebrosidase and inhibits enzyme activity","volume":"108","author":"Yap","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"108893","DOI":"10.1016\/j.isci.2024.108893","article-title":"Lysosomal stress drives the release of pathogenic \u03b1-synuclein from macrophage lineage cells via the LRRK2-Rab10 pathway","volume":"27","author":"Abe","year":"2024","journal-title":"iScience"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-017-0233-5","article-title":"\u03b1-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism","volume":"13","author":"Yun","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13024-022-00555-7","article-title":"Crosstalk of organelles in Parkinson\u2019s disease\u2014MiT family transcription factors as central players in signaling pathways connecting mitochondria and lysosomes","volume":"17","author":"Lang","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"155578","DOI":"10.1016\/j.metabol.2023.155578","article-title":"Mitochondria-SR interaction and mitochondrial fusion\/fission in the regulation of skeletal muscle metabolism","volume":"144","author":"Rieusset","year":"2023","journal-title":"Metab. Clin. Exp."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"a004424","DOI":"10.1101\/cshperspect.a004424","article-title":"ER stress and its functional link to mitochondria: Role in cell survival and death","volume":"3","author":"Malhotra","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_46","first-page":"S53","article-title":"GBA1 and The Immune System: A Potential Role in Parkinson\u2019s Disease?","volume":"12","author":"Arfaie","year":"2022","journal-title":"J. Park. Dis."},{"key":"ref_47","first-page":"101187","article-title":"Natural history of inflammation and impaired autophagy in children with Gaucher disease identified by newborn screening","volume":"42","author":"Gragnaniello","year":"2025","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Migdalska-Richards, A., Wegrzynowicz, M., Harrison, I.F., Verona, G., Bellotti, V., Spillantini, M.G., and Schapira, A.H.V. (2020). L444P Gba1 mutation increases formation and spread of \u03b1-synuclein deposits in mice injected with mouse \u03b1-synuclein pre-formed fibrils. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0238075"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1093\/brain\/awx221","article-title":"The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice","volume":"140","author":"Wegrzynowicz","year":"2017","journal-title":"Brain A J. Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"20945","DOI":"10.1038\/s41598-021-00404-5","article-title":"Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model","volume":"11","author":"Viel","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Okai, T., Sato, S., Deshpande, M., Matsumoto, S.I., Nakayama, M., Yamamoto, S., Strack-Logue, B., Hioki, T., Tanaka, M., and Proetzel, G. (2025). AAV delivery of GBA1 suppresses \u03b1-synuclein accumulation in Parkinson\u2019s disease models and restores functions in Gaucher\u2019s disease models. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0321145"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1093\/hmg\/ddv369","article-title":"Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death","volume":"24","author":"Keatinge","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.neuron.2019.12.004","article-title":"Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological \u03b1-Synuclein Insult","volume":"105","author":"Henderson","year":"2020","journal-title":"Neuron"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Grigor\u2019eva, E.V., Kopytova, A.E., Yarkova, E.S., Pavlova, S.V., Sorogina, D.A., Malakhova, A.A., Malankhanova, T.B., Baydakova, G.V., Zakharova, E.Y., and Medvedev, S.P. (2023). Biochemical Characteristics of iPSC-Derived Dopaminergic Neurons from N370S GBA Variant Carriers with and without Parkinson\u2019s Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054437"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Silveira, C.R.A., MacKinley, J., Coleman, K., Li, Z., Finger, E., Bartha, R., Morrow, S.A., Wells, J., Borrie, M., and Tirona, R.G. (2019). Ambroxol as a novel disease-modifying treatment for Parkinson\u2019s disease dementia: Protocol for a single-centre, randomized, double-blind, placebo-controlled trial. BMC Neurol., 19.","DOI":"10.1186\/s12883-019-1252-3"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.parkreldis.2021.02.003","article-title":"Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism","volume":"84","author":"Kopytova","year":"2021","journal-title":"Park. Relat. Disord."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpdd.865","article-title":"Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers","volume":"10","author":"Peterschmitt","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_58","first-page":"557","article-title":"Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson\u2019s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial","volume":"12","author":"Peterschmitt","year":"2022","journal-title":"J. Park. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.nbd.2015.06.008","article-title":"Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson\u2019s disease cells","volume":"82","author":"Ambrosi","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/ejn.14345","article-title":"Induced pluripotent stem cell-based modeling of mutant LRRK2-associated Parkinson\u2019s disease","volume":"49","author":"Weykopf","year":"2019","journal-title":"Eur. J. Neurosci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00018-024-05419-5","article-title":"Lysosomal dysfunction in \u03b1-synuclein pathology: Molecular mechanisms and therapeutic strategies","volume":"81","author":"Dai","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Bougea, A. (2024). Seeding Aggregation Assays in Lewy Bodies Disorders: A Narrative State-of-the-Art Review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251910783"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ymgme.2019.10.006","article-title":"GBA1 mutations: Prospects for exosomal biomarkers in \u03b1-synuclein pathologies","volume":"129","author":"Johnson","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Esfandiary, A., Finkelstein, D.I., Voelcker, N.H., and Rudd, D. (2022). Clinical Sphingolipids Pathway in Parkinson\u2019s Disease: From GCase to Integrated-Biomarker Discovery. Cells, 11.","DOI":"10.3390\/cells11081353"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1038\/s41467-024-49949-9","article-title":"Neuroimaging and fluid biomarkers in Parkinson\u2019s disease in an era of targeted interventions","volume":"15","author":"Zarkali","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/ene.15230","article-title":"Prevalence and genotype-phenotype correlations of GBA-related Parkinson disease in a large Chinese cohort","volume":"29","author":"Ren","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41531-025-01060-6","article-title":"Classification of GBA1 variants and their impact on Parkinson\u2019s disease: An in silico score analysis","volume":"11","author":"Lanore","year":"2025","journal-title":"NPJ Park. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","article-title":"A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies","volume":"70","author":"Nalls","year":"2013","journal-title":"JAMA Neurol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"104856","DOI":"10.1016\/j.neubiorev.2022.104856","article-title":"Exploring the link between GBA1 mutations and Dementia with Lewy bodies, A mini-review","volume":"141","author":"Gaubert","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41531-023-00501-4","article-title":"A severe neurodegenerative disease with Lewy bodies and a mutation in the glucocerebrosidase gene","volume":"9","author":"Rauramaa","year":"2023","journal-title":"npj Park. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1002\/mds.30003","article-title":"Effect of GBA1 Mutations and APOE Polymorphisms on Survival and Progression Among Ashkenazi Jews with Dementia with Lewy Bodies","volume":"39","author":"Shiner","year":"2024","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/12\/1496\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:46:56Z","timestamp":1765806416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/12\/1496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":71,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["genes16121496"],"URL":"https:\/\/doi.org\/10.3390\/genes16121496","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}